[PDF] Top 20 Rev. Bras. Reumatol. vol.53 número6 en v53n6a11
Has 10000 "Rev. Bras. Reumatol. vol.53 número6 en v53n6a11" found on our website. Below are the top 20 most common "Rev. Bras. Reumatol. vol.53 número6 en v53n6a11".
Rev. Bras. Reumatol. vol.53 número6 en v53n6a11
... Therefore, it is important for the rheumatologist to know the functions of saliva, the consequences of hyposalivation, and the methods of salivary l ow assessment, since diagnos- ing a[r] ... See full document
7
Rev. Bras. Reumatol. vol.53 número4 en v53n4a01
... The i rst major national recognition occurred in June 2004, with its inclusion in the collection of the Scientii c Electronic Library Online - Brazil (SciELO-Brazil), which included BJ[r] ... See full document
1
Rev. Bras. Reumatol. vol.53 número5 en v53n5a08
... Case 17, which demon- strated discrepant results in the CLIA (32 and 13.8 IU/mL), had been diagnosed with SLE and lupus nephritis 2 months prior, although anti-dsDNA results using both[r] ... See full document
7
Rev. Bras. Reumatol. vol.53 número5 en v53n5a09
... The results of the systematic review and meta-analysis showed that patients who were treated with ADA 40 mg ev- ery two weeks associated with MTX showed better eficacy results and lowe[r] ... See full document
12
Rev. Bras. Reumatol. vol.53 número5 en v53n5a10
... question was: What is the frequency of psychiatric comor- bidities in patients with SLE? Thus, the expected primary outcome is that psychiatric comorbidities are frequent and identiied[r] ... See full document
7
Rev. Bras. Reumatol. vol.53 número5 en v53n5a11
... sis, the vesiculobullous lesions that display distinct clinical and immunopathological features are described as bullous systemic lupus erythematosus (BSLE) and are part of the dif- fe[r] ... See full document
3
Rev. Bras. Reumatol. vol.53 número5 en v53n5a12
... We present a case of patient with ulcerative colitis, with positive c-ANCA, which progressed to hemoptysis associated with radiological i ndings consistent with pulmonary vasculitis.. [r] ... See full document
3
Rev. Bras. Reumatol. vol.53 número5 en v53n5a13
... inl iximab on the lipid proi le in a sample of patients with RA, psoriatic arthritis and SA, observed differences between the two agents, the i rst being associated with increases in T[r] ... See full document
4
Rev. Bras. Reumatol. vol.53 número5 en v53n5a14
... to demonstrate the safety of ustekinumab, Cuchacovich reported its use in patients who were refractory to photo- therapy, systemic corticosteroids and biologic therapy (in- cluding TNF [r] ... See full document
2
Rev. Bras. Reumatol. vol.53 número4 en v53n4a04
... The major inding of this study was that the frequency of entheseal abnormalities was signii cantly increased in FM patients independent of TPs involvement when compared to healthy con[r] ... See full document
6
Rev. Bras. Reumatol. vol.53 número5 en v53n5a06
... To verify whether evidence of in vivo platelet hyperac- tivity would be reproduced in vitro, analysis of platelet ag- gregation curves with different agonists in the presence of aPL-ric[r] ... See full document
5
Rev. Bras. Reumatol. vol.53 número4 en v53n4a05
... Genetic variation and signii cant association of polymorphism rs7700944 G>A of TIM-4 gene with rheumatoid arthritis susceptibility in Chinese Han and Hui populations. Arnett FC, Ed[r] ... See full document
5
Rev. Bras. Reumatol. vol.53 número4 en v53n4a08
... The present systematic review aims to discuss inl iximab-induced autoantibodies and sub- sequent onset of systemic lupus erythematosus (SLE) through the analyses of primary re- ports mea[r] ... See full document
7
Rev. Bras. Reumatol. vol.53 número4 en v53n4a10
... Nevertheless, polymyositis is a systemic autoimmune disease; therefore, the skeletal muscles may be diffusely affected, including the paravertebral muscles, which may manifest as campt[r] ... See full document
3
Rev. Bras. Reumatol. vol.53 número4 en v53n4a11
... None of the characteristics of the JIA, such as the sub- type of the disease or the presence of autoantibodies, identi- i ed a group with a higher risk for these changes, although the p[r] ... See full document
4
Rev. Bras. Reumatol. vol.53 número3 en v53n3a01
... Seven questions approach the use of biologic agents, especially anti-TNF drugs, as follows: their indication (Rec- ommendation 7); their efi cacy (Recommendation 8); their safety (Reco[r] ... See full document
2
Rev. Bras. Reumatol. vol.53 número3 en v53n3a05
... In the present study, although women with and without FM exhibited no differences regarding the level of total phys- ical activity and different types and intensities of activities per[r] ... See full document
6
Rev. Bras. Reumatol. vol.53 número3 en v53n3a07
... Introdução: O período de silêncio cutâneo (PSC) é um rel exo protetor inibitório da coluna vertebral e seus aferentes consistem em i bras nervosas A-delta. Nosso objetivo foi avaliar pacientes com i bromialgia ... See full document
8
Rev. Bras. Reumatol. vol.53 número3 en v53n3a08
... Fig. 1 – (A and B) MRI of thoracic spine on lateral view. Note the presence of a low signal lesion in T1 indicated by the arrows (A) before and (B) after contrast administration, with a homogeneous enhancement. (from: ... See full document
7
Rev. Bras. Reumatol. vol.53 número5 en v53n5a07
... In light of the issues mentioned above, the objectives of the current study were as follows: (1) to characterize the main symptoms of scleroderma and their impact on scleroderma patie[r] ... See full document
7
temas relacionados